NASDAQ:XENTIntersect ENT Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intersect ENT Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.53 -0.28 (-2.85 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$9.20Now: $9.53▼$10.0150-Day Range$8.95MA: $19.79▼$28.9852-Week Range$5.97Now: $9.53▼$34.28Volume563,623 shsAverage Volume1.16 million shsMarket Capitalization$307.82 millionP/E RatioN/ADividend YieldN/ABeta1.36 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingIntersect ENT has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.83, Intersect ENT has a potential upside of 171.1% from its current price of $9.53.Amount of Analyst CoverageIntersect ENT has only been the subject of 2 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesIntersect ENT has received 398 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntersect ENT has received 291 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntersect ENT has received 57.76% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote “Outperform” if you believe XENT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntersect ENT does not currently pay a dividend.Dividend GrowthIntersect ENT does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intersect ENT insiders have bought more of their company's stock than they have sold. Specifically, they have bought $295,863.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Intersect ENT is held by insiders.Percentage Held by Institutions96.46% of the stock of Intersect ENT is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Intersect ENT are expected to decrease by -13.94% in the coming year, from ($1.65) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intersect ENT is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intersect ENT is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntersect ENT has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.01 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENT Previous Symbol CUSIPN/A CIK1271214 Webhttp://www.intersectent.com/ Phone650-641-2100Debt Debt-to-Equity Ratio0.09 Current Ratio6.82 Quick Ratio5.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$109.14 million Price / Sales2.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book2.54Profitability EPS (Most Recent Fiscal Year)($1.37) Net Income$-42,990,000.00 Net Margins-39.39% Return on Equity-36.92% Return on Assets-31.19%Miscellaneous Employees393 Outstanding Shares32,300,000Market Cap$307.82 million Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive XENT News and Ratings via Email Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:XENT Rates by TradingView Intersect ENT (NASDAQ:XENT) Frequently Asked Questions How has Intersect ENT's stock been impacted by COVID-19 (Coronavirus)? Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XENT shares have decreased by 55.7% and is now trading at $9.53. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Intersect ENT? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intersect ENT. When is Intersect ENT's next earnings date? Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Intersect ENT. How were Intersect ENT's earnings last quarter? Intersect ENT Inc (NASDAQ:XENT) issued its earnings results on Monday, February, 24th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.10. The medical equipment provider earned $31.70 million during the quarter, compared to analyst estimates of $31.60 million. Intersect ENT had a negative return on equity of 36.92% and a negative net margin of 39.39%. The company's revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) earnings per share. View Intersect ENT's earnings history. What guidance has Intersect ENT issued on next quarter's earnings? Intersect ENT issued an update on its FY 2020 Pre-Market earnings guidance on Monday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115-119 million, compared to the consensus revenue estimate of $119.41 million. What price target have analysts set for XENT? 8 brokers have issued 1-year price targets for Intersect ENT's stock. Their forecasts range from $20.00 to $30.00. On average, they expect Intersect ENT's share price to reach $25.83 in the next twelve months. This suggests a possible upside of 171.1% from the stock's current price. View analysts' price targets for Intersect ENT. What are Wall Street analysts saying about Intersect ENT stock? Here are some recent quotes from research analysts about Intersect ENT stock: 1. Northland Securities analysts commented, "We are upgrading Intersect ENT to a Market Perform rating. We had downgraded the stock immediately after the Q1 report. The stock has reached our price target, hence the ratings change. We note though, the ratings change does not reflect a fundamental change in outlook, at least for now." (7/10/2019) 2. According to Zacks Investment Research, "Over the past year, shares of Intersect ENT have underperformed the industry it belongs to. Escalating costs and expenses continue to weigh on the company’s margins. This apart, the pricing scenario is persistently tough for Intersect ENT. Strong competitors in the large medical device market also pose a tough challenge. On a positive note, within a short span of time, the SINUVA line of business has made a considerable progress with market access and field force balance. Within the company’s Propel line, Intersect ENT registered 10% growth in the top line during the fourth quarter 2018, driven by an expanded usage of Contour among both the current as well as the new physicians." (5/3/2019) Has Intersect ENT been receiving favorable news coverage? Press coverage about XENT stock has been trending very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intersect ENT earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutIntersect ENT. Are investors shorting Intersect ENT? Intersect ENT saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,990,000 shares, an increase of 20.6% from the February 13th total of 1,650,000 shares. Based on an average daily volume of 791,100 shares, the days-to-cover ratio is currently 2.5 days. Currently, 6.5% of the shares of the company are sold short. View Intersect ENT's Current Options Chain. Who are some of Intersect ENT's key competitors? Some companies that are related to Intersect ENT include Inspire Medical Systems (INSP), Atrion (ATRI), Inovio Pharmaceuticals (INO), Silk Road Medical (SILK), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Cerus (CERS), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Cryolife (CRY), Orthopediatrics (KIDS), Orthofix Medical (OFIX), LeMaitre Vascular (LMAT), SurModics (SRDX) and Anika Therapeutics (ANIK). What other stocks do shareholders of Intersect ENT own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), COSTAMARE INC/SH (CMRE), Mimecast (MIME), Air Transport Services Group (ATSG), EOG Resources (EOG), Netflix (NFLX), Gilead Sciences (GILD) and AbbVie (ABBV). Who are Intersect ENT's key executives? Intersect ENT's management team includes the following people: Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)Ms. Christine R. Kowalski, Chief Operations Officer (Age 62) What is Intersect ENT's stock symbol? Intersect ENT trades on the NASDAQ under the ticker symbol "XENT." How do I buy shares of Intersect ENT? Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intersect ENT's stock price today? One share of XENT stock can currently be purchased for approximately $9.53. How big of a company is Intersect ENT? Intersect ENT has a market capitalization of $307.82 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 393 workers across the globe. View additional information about Intersect ENT. What is Intersect ENT's official website? The official website for Intersect ENT is http://www.intersectent.com/. How can I contact Intersect ENT? Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Percentage Decliners
